> HOW IT WORKS · WHAT THE STUDIES FOUND
What did Tirzepatide phase 3 studies, the big final tests, show?
Large studies found blood sugar along with body weight go down. The drug adds another gut-hormone action to GLP-1. Other studies covered the heart, sleep, and liver.
> What Tirzepatide studies showed and could not prove
What have studies shown about Tirzepatide? In large tests, people had blood sugar along with body weight go down. The drug adds another gut-hormone action to GLP-1. In direct tests, shots acting like that hormone alone brought smaller changes.
The limits come first. These were phase 3 studies, the large final tests before approval. The figures describe whole groups. The main weight study lasted 72 weeks. At the top dose, adults with obesity lost 20.9% on average from their starting weight [1]. For adults with type 2 diabetes, the blood test that reflects sugar over the last few months dropped 2.30 points over 40 weeks [2]. In a direct weight study, Tirzepatide led by 6.5 percentage points [3]. Later studies examined heart failure, sleep apnea, and scars in the liver.
What Tirzepatide and the GLP-1 gut hormone do after you eat
What changes after you eat? Two hormones from your gut help steady sugar levels and ease hunger. One is called GLP-1. When sugar is high, these hormones ask your pancreas for more insulin. The hormones also lower glucagon, a hormone that raises blood sugar. Your stomach then sends food onward more slowly, so hunger may ease.
Older shots copy GLP-1 alone. Tirzepatide adds the other gut-hormone action. Tests in cells found the other effect was stronger than its GLP-1 effect. Scientists think this difference may change how much insulin the pancreas sends out [8]. That is an idea from cell work, not proof of what happens in your body.
In 2022, close-up images showed how the drug can attach where GLP-1 and the other hormone normally act [32]. Tirzepatide has a 39-amino-acid chain, made from pieces your body uses to build proteins. These images help explain the drug's design. They can't tell whether it will help you.
What makes the Tirzepatide peptide last a week
Tirzepatide is a lab-made peptide, which means a small chain made of protein pieces. It is a 39-amino-acid chain, but that count doesn't affect how you use it. Its makers added three kinds of parts that help it last: small spacers, a linker, and a fat-like piece. (1) There are 2 short spacers. (2) The linker joins them to the fat-like piece. These parts simply slow the drug's exit from your blood.
The fat-like piece joins albumin, a protein found throughout the blood, so your body removes the drug slowly. About half is gone after 5 days, making weekly use possible [7].
Older drugs copy GLP-1 alone. Tirzepatide works through GLP-1 plus the other hormone from the gut. Its design explains why the shot lasts. It can't tell us how much the medicine will help you.
What the main Tirzepatide phase 3 studies found before approval
These main studies were the large final tests before approval. Many thousands of people took part across them. Chance decided each person's treatment group.
SURPASS-2 followed 1879 adults for 40 weeks. All had type 2 diabetes. In SURPASS-2, weekly doses of 5/10/15 mg lowered the blood test that reflects sugar over the last few months. The other weekly medicine copied GLP-1, one gut hormone, and lowered it less. Each Tirzepatide dose also brought greater weight loss [2].
SURMOUNT-1 followed 2539 adults for 72 weeks. The group had obesity, not diabetes. Entry required a height-and-weight number called body mass index 30 or higher. That number links a person's weight to height. People could also enter at 27 or higher when weight was already harming health. People lost 15.0% on average at 5 mg; the loss was 19.5% at 10 mg and 20.9% at 15 mg. Placebo, an injection without medicine, led to 3.1% loss. Problems in the stomach and bowels appeared most often, and most stayed mild or moderate [1].
SURMOUNT-5 followed 751 adults for 72 weeks. They had obesity; none had type 2 diabetes. Each person took as much of the assigned medicine as they could bear. The other shot copied GLP-1 alone. Average loss was 20.2% with Tirzepatide and 13.7% with the other shot. More Tirzepatide users lost at least 10/15/20/25% [3].
What Tirzepatide changed in sleep, heart, and liver studies
Other studies asked about health beyond weight or blood sugar. Each involved a certain kind of adult, so the findings may not fit you.
Sleep apnea: Adults had obesity and sleep apnea judged moderate or severe. With Tirzepatide, they had fewer breathing pauses during every sleeping hour. This finding supported another FDA approval [12].
Heart failure: Each adult had obesity as well as a form of heart failure where the heart still pumps its usual share of blood. They could exercise more with Tirzepatide. Fewer died from heart trouble or had worsening heart failure [13].
Fatty liver illness: Adults had fat buildup plus liver scars. More people taking Tirzepatide lost signs of the illness and had less scarring than those given placebo, an injection containing no medicine [11].
What a Tirzepatide injection does during the week
A Tirzepatide injection goes into the fat under your skin. This is the only form tested for approval and in the key studies. The shot can go in the belly, thigh, or upper arm.
The drug clings to albumin, one protein carried in your blood, which slows its exit. About half is gone after 5 days [7]. In studies, people began with 2.5 mg each week for 4 weeks. Doses then rose through 5, 7.5, 10, 12.5, and 15 mg. The doses used for longer care were 5, 10, and 15 mg.
These figures describe the studies. They aren't your own dose plan. The tirzepatide dosage section explains the label.
What Tirzepatide reviews found across many studies
Tirzepatide reviews join results from several studies. They found bigger changes than with medicine that copies GLP-1, one gut hormone. The added action beyond GLP-1 may matter. Reviews also recorded extra trouble in the stomach and bowels.
[+] People had more stomach or bowel trouble with Tirzepatide than with placebo. Placebo was a shot with no medicine [15]. [+] Two reviews found more illness affecting the gallbladder or the tubes carrying bile. One 95% range showed a likely rise but left its size uncertain. The other 95% range led to the same plain finding [4] [21]. [note] For pancreas swelling, the findings left too much doubt for a clear answer [4]. [+] One large review found serious harm about as often with Tirzepatide as with placebo [33]. [+] People taking Tirzepatide were 32% more likely to stop for side effects than those taking dulaglutide, another weekly diabetes shot [10]. The raw stop rates aren't given here, so that percent doesn't show how many people stopped.
You can find every paper under Tirzepatide references.